Belatacept and Kidney Transplant Video Gallery

The Food and Drug Administration (FDA) has approved the drug Nulojix (belatacept) for the prevention of graft rejection after kidney transplants. In this kidney transplant video, Christian P. Larsen, MD, DPhil, Dean of the Emory University School of Medicine and Joseph B. Whitehead Professor, Department of Surgery at Emory University School of Medicine, provides a nutshell explanation of how the transplant drug works, how it might impact kidney transplant patients and what type of work went into the drug's development. The immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard drug cyclosporine.

New Transplant Drug Belatacept: How It Works
Christian P. Larsen, Dean, Emory University School of Medicine, provides a nutshell explanation of a breakthrough in transplant medicine.

Transplant Drug Belatacept Shows Promise for Kidney Transplant
Christian P. Larsen, Dean, Emory University School of Medicine, explains why Belatacept represents a breakthrough in transplant medicine.

New Transplant Drug Belatacept: Drug Research and Development
Christian P. Larsen, Dean, Emory University School of Medicine, on the years of work that resulted in FDA approval of Belatacept, a breakthrough in transplant medicine.